Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : The Naked Truth - Big Kahuna a Myth -- Ignore unavailable to you. Want to Upgrade?

To: Cynic 2005 who wrote (37356)	4/30/1999 4:34:00 AM
From: John Pitera	Read Replies (1) \| Respond to of 86076

Mohan, thanks for some insight on CNTO, they appear cheap on a valuation basis for a biotech company I think that Cnto's Reopro anti-clotting treatment is a super high growth business, I was at the ST Lukes medical center, visiting a friend getting a stent last month and it is a dramtic growth industry. The demographics will only enhance this trend going forward. A get together with one of the top stent companies such as GDT, or BSX, or one of the others would yield synergies I'm sure. 'm hearing there is a smattering of takeout rumors on the Street, and there also have been rumors...about a potential co-promotion deal" to team Centocor's anti-clotting treatment ReoPro with a stent manufacturer, said Robert Toth, biotechnology analyst, Vector Securities International. "We also believe the company's cardiovascular franchise is second to none. "Expectations, in general, appear extremely low, making Centocor, in our view, the most undervalued top-tier biotech stock," said Silverman. "Despite lowering our estimates, our confidence in Remicade growth is higher than ever, with what is ostensibly the worst quarter out of the way, higher projected growth than its peers' and the stock trading at a meaningful discount to the top-tier biotech group." " there is alot to be said for the bullish observations. imo I see cnto is moving up to the 45 resistance, I would expect it to be able to take that level out and challenge the old high at 53-54 $ a move above the old highs would be very bullish indeed.